Thursday, October 31, 2024

11:50 AM - 12:35 PM

---

Details

Biotechnology and emerging biopharmaceutical companies are an important and high-growth segment of Australia’s clinical trial landscape.  IQVIA’s analysis of Australian and international clinical trials reveals the resilience of Australia’s clinical trial sector in the context of a reduction in clinical trial activity following the COVID-19 peak in 2020/21, and highlights areas of competitive strength for Australia, but also notes emerging capacity constraints and opportunities to address them.  This panel discussion will explore the strengths and key challenges facing sites and sponsors in Australia, and the evolving policy approaches to strengthen the sector, including the National One Stop Shop.

---

Speaker